MaxCyte (MXCT) News Today → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free MXCT Stock Alerts $4.74 +0.01 (+0.21%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineWilliam Blair Comments on MaxCyte, Inc.'s Q1 2025 Earnings (NASDAQ:MXCT)americanbankingnews.com - May 11 at 5:58 AMMaxCyte, Inc. Forecasted to Post Q1 2025 Earnings of ($0.14) Per Share (NASDAQ:MXCT)marketbeat.com - May 10 at 9:42 AMMaxCyte (NASDAQ:MXCT) Sees Large Volume Increasemarketbeat.com - May 8 at 3:54 PMMaxCyte shares rise amid double-digit revenue increaselse.co.uk - May 8 at 11:06 AMMaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...finance.yahoo.com - May 8 at 6:05 AMMXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024investorplace.com - May 7 at 10:05 PMMaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidanceglobenewswire.com - May 7 at 4:05 PMMaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidanceglobenewswire.com - May 7 at 4:05 PMMaxCyte Inc MYE0morningstar.com - May 3 at 7:29 PMMaxCyte, Inc. (MXCT)finance.yahoo.com - April 26 at 3:57 PMMaxCyte (NASDAQ:MXCT) Receives Overweight Rating from Stephensmarketbeat.com - April 23 at 11:56 AMMaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024globenewswire.com - April 10 at 8:05 AMMesa Laboratories maintains quarterly dividend of $0.16msn.com - April 5 at 1:52 AMMaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)globenewswire.com - April 2 at 8:05 AMInsider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 5,000 Shares of Stockinsidertrades.com - March 29 at 8:56 AMJohn Joseph Johnston Sells 5,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stockmarketbeat.com - March 28 at 7:55 PMWillis Investment Counsel Invests $2.59 Million in MaxCyte, Inc. (NASDAQ:MXCT)marketbeat.com - March 20 at 6:53 PMDowngrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Termfinance.yahoo.com - March 17 at 8:04 AMMaxCyte, Inc: MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidancefinanznachrichten.de - March 15 at 8:07 AMMaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimatesfinance.yahoo.com - March 14 at 10:45 AMMaxCyte (NASDAQ:MXCT) Receives Outperform Rating from William Blairmarketbeat.com - March 13 at 10:27 AMMaxCyte Shares Rise 13% After 4Q Beat, Reaffirmed Guidancemarketwatch.com - March 13 at 8:22 AMMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidanceglobenewswire.com - March 12 at 4:05 PMMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidanceglobenewswire.com - March 12 at 4:05 PMMaxCyte, Inc.: MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Resultsfinanznachrichten.de - March 6 at 4:53 PMWilliam Blair Reiterates "Outperform" Rating for MaxCyte (NASDAQ:MXCT)marketbeat.com - March 5 at 11:43 AMMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Resultsglobenewswire.com - March 4 at 4:05 PMMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Resultsglobenewswire.com - March 4 at 4:05 PMBlair William & Co. IL Boosts Stock Position in MaxCyte, Inc. (NASDAQ:MXCT)marketbeat.com - February 19 at 5:57 AMMaven Securities LTD Buys New Position in MaxCyte, Inc. (NASDAQ:MXCT)marketbeat.com - February 16 at 8:21 AMMaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferencesfinance.yahoo.com - February 9 at 8:25 AMMaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancersfinance.yahoo.com - January 30 at 9:41 AMMaxCyte Signs SPL Agreement With Imugenemarkets.businessinsider.com - January 23 at 1:02 PMWhy Cell Engineering Company MaxCyte Shares Are Up Todaymsn.com - January 9 at 1:07 PMCOMM, NKTX and AVIR are among after hour moversseekingalpha.com - January 9 at 8:07 AMMaxCyte Stock (NASDAQ:MXCT) Dividends: History, Yield and Datesbenzinga.com - January 5 at 9:06 AMMaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipelinefinance.yahoo.com - January 3 at 9:13 AMMaxCyte, Inc. (NASDAQ:MXCT) Sees Significant Growth in Short Interestmarketbeat.com - January 2 at 8:54 PMMaxCyte, Inc: MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Directorfinanznachrichten.de - January 2 at 7:55 AMMaxCyte gets new CEO and Presidentmsn.com - January 2 at 7:55 AMMaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Directorfinance.yahoo.com - January 2 at 2:55 AMMaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 5,000 Sharesmarketbeat.com - December 28 at 6:44 PMWith 74% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big gunsfinance.yahoo.com - December 15 at 7:35 AMFY2023 EPS Estimates for MaxCyte, Inc. (NASDAQ:MXCT) Raised by Analystmarketbeat.com - December 14 at 7:13 AMMaxCyte Names Maher Masoud CEOmarketwatch.com - December 11 at 5:49 PMMaxCyte announces departure of founder and CEO Doug Doerflermsn.com - December 11 at 5:49 PMMaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023markets.businessinsider.com - December 11 at 5:49 PMMaxCyte, Inc. (NASDAQ:MXCT) Stock Holdings Trimmed by Blue Water Life Science Advisors LPmarketbeat.com - December 11 at 7:55 AMInsider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT)finance.yahoo.com - December 7 at 1:34 PMMaxCyte, Inc.: MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidancefinanznachrichten.de - November 9 at 9:31 AM Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address The 2024 Gold Rush: Unleashing Market Potential (Ad)Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights. Get your free information kit NOW, before it's too late. MXCT Media Mentions By Week MXCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MXCT News Sentiment▼0.880.58▲Average Medical News Sentiment MXCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MXCT Articles This Week▼131▲MXCT Articles Average Week Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MeiraGTx News OmniAb News Absci News Harvard Bioscience News Inotiv News Anika Therapeutics News TScan Therapeutics News Beauty Health News Bioventus News Tourmaline Bio News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MXCT) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe Exchange[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
